| Literature DB >> 32067593 |
Marisa H Sobel1, Tiffany R Sanchez1, Miranda R Jones2, Joel D Kaufman3, Kevin A Francesconi4, Michael J Blaha5, Dhananjay Vaidya5, Daichi Shimbo6, Walter Gossler4, Mary V Gamble1, Jeanine M Genkinger7, Ana Navas-Acien1.
Abstract
Background Arsenic-related cardiovascular effects at exposure levels below the US Environmental Protection Agency's standard of 10 μg/L are unclear. For these populations, food, especially rice, is a major source of exposure. We investigated associations of rice intake, a marker of arsenic exposure, with subclinical cardiovascular disease (CVD) markers in a multiethnic population. Methods and Results Between 2000 and 2002, MESA (Multi-Ethnic Study of Atherosclerosis) enrolled 6814 adults without clinical CVD. We included 5050 participants with baseline data on rice intake and markers of 3 CVD domains: inflammation (hsCRP [high-sensitivity C-reactive protein], interleukin-6, and fibrinogen), vascular function (aortic distensibility, carotid distensibility, and brachial flow-mediated dilation), and subclinical atherosclerosis at 3 vascular sites (carotid intima-media thickness, coronary artery calcification, and ankle-brachial index). We also evaluated endothelial-related biomarkers previously associated with arsenic. Rice intake was assessed by food frequency questionnaire. Urinary arsenic was measured in 310 participants. A total of 13% of participants consumed ≥1 serving of rice/day. Compared with individuals consuming <1 serving of rice/week, ≥1 serving of rice/day was not associated with subclinical markers after demographic, lifestyle, and CVD risk factor adjustment (eg, geometric mean ratio [95% CI] for hsCRP, 0.98 [0.86-1.11]; aortic distensibility, 0.99 [0.91-1.07]; and carotid intima-media thickness, 0.98 [0.91-1.06]). Associations with urinary arsenic were similar to those for rice intake. Conclusions Rice intake was not associated with subclinical CVD markers in a multiethnic US population. Research using urinary arsenic is needed to assess potential CVD effects of low-level arsenic exposure. Understanding the role of low-level arsenic as it relates to subclinical CVD may contribute to CVD prevention and control.Entities:
Keywords: arsenic; cardiovascular disease; inflammation; rice
Year: 2020 PMID: 32067593 PMCID: PMC7070216 DOI: 10.1161/JAHA.119.015658
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Study design flow chart. Sample size flow chart for analyses based on rice intake in MESA (Multi‐Ethnic Study of Atherosclerosis). A total of 6814 participants were recruited to MESA between 2000 and 2002. Rice intake was assessed via food frequency questionnaire (FFQ) at baseline. Participants with missing rice information (n=658), unreliable dietary information (n=436), or missing adjustment variables (n=670) at baseline were excluded. A subset had brachial flow‐mediated dilation measurements (n=2702) and an aortic distensibility assessment (n=2759). Urine arsenic was measured in a stratified random sample of 310 participants at baseline, and 246 remained in our final data set for most outcomes. ABI indicates ankle‐brachial index; BP, blood pressure; CAC, coronary artery calcium; CIMT, coronary intima‐media thickness; FMD, flow‐mediated dilation; hsCRP, high‐sensitivity C‐reactive protein; ICAM‐1, intercellular adhesion molecule‐1; IL‐6, interleukin‐6; LDL‐c, low‐density lipoprotein cholesterol; MMP‐9, matrix metallopeptidase 9.
Baseline Characteristics of MESA Participants by Rice Intake and Urinary Arsenic (2000–2002)
| Characteristic | Overall | Rice Intake |
| ||
|---|---|---|---|---|---|
| <1 Serving/wk | 1–6 Servings/wk | ≥1 Serving/d | |||
| (n=5050) | (n=2028) | (n=2383) | (n=639) | ||
| Men | 2331 (46) | 896 (44) | 1142 (48) | 293 (46) | 0.045 |
| Age, y | 62 (53–70) | 64 (55–71) | 60 (52–69) | 63 (54–71) | <0.001 |
| Race/ethnicity | <0.001 | ||||
| White | 2076 (41) | 1221 (60) | 845 (36) | 10 (2) | |
| Asian | 657 (13) | 15 (1) | 174 (7) | 468 (73) | |
| Black | 1222 (24) | 571 (28) | 620 (26) | 31 (5) | |
| Hispanic | 1095 (22) | 221 (11) | 744 (31) | 130 (20) | |
| Site | <0.001 | ||||
| Salem, NC | 804 (16) | 459 (23) | 343 (14) | 2 (0) | |
| New York, NY | 715 (14) | 192 (10) | 449 (19) | 74 (12) | |
| Baltimore, MD | 726 (14) | 426 (21) | 291 (12) | 9 (1) | |
| St Paul, MN | 838 (17) | 445 (22) | 372 (16) | 21 (3) | |
| Chicago, IL | 937 (19) | 347 (17) | 438 (18) | 152 (24) | |
| Los Angeles, CA | 1030 (20) | 159 (8) | 490 (21) | 381 (60) | |
| Education | <0.001 | ||||
| High school or less | 1781 (35) | 615 (30) | 816 (34) | 350 (55) | |
| Some college | 1143 (23) | 521 (26) | 535 (23) | 87 (14) | |
| College degree or more | 2126 (42) | 892 (44) | 1032 (43) | 202 (32) | |
| BMI, kg/m2 | 27 (24–31) | 28 (25–31) | 28 (25–31) | 25 (22–27) | <0.001 |
| Energy intake, kcal | 1397 (1031–1881) | 1309 (989–1749) | 1523 (1117–2030) | 1197 (894–1660) | <0.001 |
| Alternate Healthy Eating Index score | 42 (34–50) | 40 (32–49) | 43 (35–52) | 44 (38–51) | <0.001 |
| Physical activity, MET | 67 (33–124) | 72 (37–132) | 71 (36–129) | 41 (21–84) | <0.001 |
| Hypertension | 2177 (43) | 934 (46) | 982 (41) | 261 (41) | 0.002 |
| Diabetes mellitus | 1224 (24) | 460 (23) | 587 (25) | 177 (28) | 0.03 |
| Family history of myocardial infarction | 2003 (40) | 900 (44) | 944 (40) | 159 (25) | <0.001 |
| Current cigarette use | 607 (12) | 271 (13) | 285 (12) | 51 (8) | <0.001 |
| Pack‐years | 17 (6–33) | 19 (8–36) | 15 (5–30) | 14 (5–29) | <0.001 |
| Urine arsenic/creatinine, μg/g | 3.08 (1.96–4.69) | 2.34 (1.55–3.09) | 3.27 (1.95–4.62) | 4.36 (3.14–6.88) | <0.001 |
Data are presented as number (percentage) or median (interquartile range). BMI indicates body mass index; MESA, Multi‐Ethnic Study of Atherosclerosis; MET, metabolic equivalent.
Among ever smokers only.
Sum of inorganic arsenic, methylarsonate, and dimethylarsinate, corrected for arsenobetaine levels.
Association of Rice Intake and Urinary Arsenic With Domains of Subclinical CVD in MESA, United States, 2000 to 2002
| Variable | Rice Intake | Urinary Arsenic | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <1 Serving/wk | 1–6 Servings/wk | ≥1 Serving/d |
| Per 2.64 μg/g Creatinine | |||||
| n | Value (95% CI) | n | Value (95% CI) | n | Value (95% CI) | n | Value (95% CI) | ||
| Inflammation markers | |||||||||
| hsCRP (mg/L), GMR | 2028 | 1.00 (Reference) | 2383 | 0.97 (0.91 to 1.03) | 639 | 0.98 (0.86 to 1.11) | 0.4 | 246 | 1.02 (0.84 to 1.23) |
| hsCRP ≥2 mg/L, OR | 1046/982 | 1.00 (Reference) | 1136/1247 | 0.95 (0.82 to 1.09) | 183/456 | 0.84 (0.62 to 1.13) | 0.3 | 101/145 | 1.20 (0.75 to 1.91) |
| Interleukin‐6 (pg/mL), GMR | 2028 | 1.00 (Reference) | 2383 | 0.99 (0.95 to 1.03) | 639 | 0.98 (0.91 to 1.06) | 0.6 | 246 | 0.99 (0.88 to 1.12) |
| Fibrinogen (mg/dL), GMR | 2028 | 1.00 (Reference) | 2383 | 1.00 (0.99 to 1.01) | 639 | 1.01 (0.99 to 1.03) | 0.5 | 246 | 1.00 (0.96 to 1.03) |
| Arsenic‐specific inflammation markers | |||||||||
| E‐selectin (ng/mL), GMR | 298 | 1.00 (Reference) | 385 | 1.11 (1.03 to 1.19) | 99 | 1.11 (0.96 to 1.28) | 0.02 | 0 | ··· |
| ICAM‐1 (ng/mL), GMR | 779 | 1.00 (Reference) | 992 | 1.00 (0.97 to 1.03) | 232 | 1.02 (0.97 to 1.07) | 0.7 | 75 | 1.07 (0.97 to 1.19) |
| MMP‐9 (ng/mL), GMR | 298 | 1.00 (Reference) | 385 | 0.99 (0.91 to 1.08) | 99 | 0.99 (0.85 to 1.17) | 0.9 | 0 | ··· |
| Vascular function | |||||||||
| FMD, MD | 920 | 0.00 (Reference) | 1316 | 0.06 (−0.19 to 0.32) | 466 | 0.41 (−0.03 to 0.85) | 0.1 | 142 | −0.02 (−0.71 to 0.67) |
| Carotid distensibility (10−3 mm Hg), MD | 2028 | 0.00 (Reference) | 2383 | −0.02 (−0.08 to 0.04) | 639 | −0.10 (−0.22 to 0.02) | 0.2 | 246 | −0.05 (−0.22 to 0.13) |
| Aortic distensibility (mm Hg−1), GMR | 1130 | 1.00 (Reference) | 1334 | 0.97 (0.93 to 1.01) | 295 | 0.99 (0.91 to 1.07) | 0.3 | 128 | 0.96 (0.82 to 1.12) |
| Subclinical atherosclerosis | |||||||||
| CIMT (internal), GMR | 2028 | 1.00 (Reference) | 2383 | 1.01 (0.98 to 1.04) | 639 | 0.97 (0.92 to 1.02) | 0.7 | 246 | 0.98 (0.91 to 1.06) |
| CIMT (common), GMR | 2028 | 1.00 (Reference) | 2383 | 1.00 (0.99 to 1.01) | 639 | 0.97 (0.95 to 1.00) | 0.3 | 246 | 0.99 (0.96 to 1.03) |
| CAC >0, OR | 1105/923 | 1.00 (Reference) | 1076/1307 | 0.93 (0.79 to 1.08) | 308/331 | 0.94 (0.69 to 1.27) | 0.4 | 117/129 | 0.99 (0.61 to 1.60) |
| CAC >75th percentile, OR | 267/838 | 1.00 (Reference) | 284/792 | 0.93 (0.74 to 1.16) | 71/237 | 0.67 (0.42 to 1.07) | 0.2 | 27/90 | 0.99 (0.61 to 1.60) |
| ABI <1, OR | 284/1744 | 1.00 (Reference) | 219/2164 | 0.89 (0.71 to 1.10) | 54/585 | 0.85 (0.53 to 1.37) | 0.3 | 20/226 | 1.01 (0.46 to 2.21) |
Models adjusted for age, sex, race/ethnicity, education, education, smoking status, pack‐years, exercise, body mass index, diabetes mellitus, hypertension, hyperlipidemia, estimated glomerular filtration rate, energy intake, and alternative Healthy Eating Index. ABI indicates ankle‐brachial index; CAC, coronary artery calcium; CIMT, carotid intima‐media thickness; CVD, cardiovascular disease; FMD, flow‐mediated dilation; GMR, geometric mean ratio; hsCRP, high‐sensitivity C‐reactive protein; ICAM‐1, intercellular adhesion molecule‐1; MD, mean difference; MESA, Multi‐Ethnic Study of Atherosclerosis; MMP‐9, matrix metallopeptidase 9; OR, odds ratio.
Number (yes/no).